Clinical efficacy analysis for amlodipine besylate and benazepril hydrochloride tablets in treatment of essential hypertension

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025826

Enrollment

Unknown

Registered

2019-09-10

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension

Interventions

single arm:All people take amlodipine besylate and benazepril hydrochloride tablets

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) All patients met the diagnostic criteria for essential hypertension; 2) patients were able to communicate well with medical staff; 3) aged 18-75 years; 4) patients volunteered to participate in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1) uncooperative patients; 2) contraindication of benazepril or amlodipine.

Design outcomes

Primary

Measure	Time frame
24 hour ambulatory blood pressure;Left atrial diameter;	—

Countries

China

Contacts

Public ContactYanqiu Xing

Department of Geriatrics, Qilu Hospital of Shandong University

xingyanqiu@sina.com+86 18560082269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026